Shree Ganesh Biotech India Ltd Slides to Record Low Amid Prolonged Downtrend

Price Action and Market Context

The stock’s recent trajectory has been notably weak, with a 3-month loss of 20% compared to a Sensex decline of just 1.65%. Over the last five years, Shree Ganesh Biotech India Ltd has plummeted by 92.99%, a stark contrast to the Sensex’s 27.72% gain over the same period. The share price currently trades below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a firmly entrenched bearish trend. Immediate support rests at the 52-week low of Rs 0.48, with resistance levels at Rs 0.50 and Rs 0.56, corresponding to the 20-day and 100-day moving averages respectively. The stock’s delivery volumes have increased by over 22% in the past month, indicating heightened trading activity amid the sell-off. what is driving such persistent weakness in Shree Ganesh Biotech India Ltd when the broader market is in rally mode?

Valuation Metrics Reflect Elevated Risk

The valuation landscape for Shree Ganesh Biotech India Ltd is complex and indicative of the challenges it faces. The company is loss-making, with a trailing twelve-month price-to-earnings ratio not applicable due to negative earnings. The price-to-book value ratio stands at a low 0.31x, suggesting the market values the company at less than one-third of its book equity. Enterprise value to EBITDA and EBIT ratios are both negative at -11.09x, reflecting the absence of positive operating earnings. Meanwhile, the EV to sales multiple is 3.89x, which is not excessively high but must be interpreted cautiously given the negative profitability. These valuation metrics suggest caution may be warranted for investors considering exposure at these levels. should you be looking at Shree Ganesh Biotech India Ltd as a potential entry point or is there more downside ahead?

Quarterly Financial Performance Highlights

The latest quarterly results for Shree Ganesh Biotech India Ltd reveal a flat financial trend with operating losses deepening. The company reported its lowest PBDIT at Rs -0.89 crore and a corresponding PBT less other income also at Rs -0.89 crore. Earnings per share for the quarter stood at a negative Rs 0.01, marking the lowest level recorded. These figures underscore the ongoing difficulties in generating positive operating cash flows. The negative EBITDA of Rs -1.76 crore further highlights the strain on core profitability. Despite the stock’s sharp decline, profits have fallen by 86% over the past year, indicating that the share price drop is broadly aligned with deteriorating earnings. is this a one-quarter anomaly or the start of a structural revenue problem?

Quality and Capital Structure Considerations

Assessing the company’s quality metrics reveals a below-average profile. Over the past five years, sales have contracted by 31.22%, while EBIT has declined by a substantial 204.98%. The average EBIT to interest coverage ratio is a weak 0.35x, signalling limited ability to service debt obligations comfortably. However, the company benefits from a low leverage position with negative net debt and no promoter share pledging. Institutional ownership is minimal at 1.42%, with the majority of shares held by non-institutional investors. Return on capital employed and return on equity remain subdued at 1.52% and 2.54% respectively, reflecting low profitability relative to invested capital and shareholders’ funds. how much does the weak financial quality weigh on the stock’s outlook?

Key Data at a Glance

Technical Indicators Confirm Bearish Momentum

The technical outlook for Shree Ganesh Biotech India Ltd remains firmly bearish. The overall trend shifted to bearish on 16 June 2026 at Rs 0.58 and has persisted since. Weekly MACD and KST indicators are bearish, while monthly MACD shows mild bullishness, suggesting some divergence in momentum across timeframes. Bollinger Bands indicate mild to full bearishness, and the stock trades below all major moving averages. Immediate resistance is seen at Rs 0.50, near the 20-day moving average, with stronger resistance at Rs 0.56 and Rs 0.59, corresponding to the 100-day and 200-day moving averages. Delivery volumes have risen by 22% over the past month, reflecting increased investor activity amid the downtrend. does the technical picture suggest any near-term relief or further downside risk?

Balancing the Bear Case and Silver Linings

The persistent decline in Shree Ganesh Biotech India Ltd is underpinned by weak profitability, negative operating cash flows, and subdued quality metrics. The company’s inability to generate positive earnings and its poor interest coverage ratio highlight financial stress. However, the absence of promoter share pledging and low leverage provide some structural stability. The stock’s valuation at a fraction of book value reflects the market’s cautious stance. Should you buy, sell, or hold at these levels? Explore the complete multi-factor analysis of Shree Ganesh Biotech India Ltd to find out what the data signals at this all-time low.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →